CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

<b>Background</b>: Patients with refractory and relapsed acute myeloid leukemia (R/R AML) face a dismal prognosis. CAR-T therapy has emerged as a potential treatment option. This study assesses the available clinical evidence on CAR-T in R/R AML, focusing on safety and efficacy outcomes....

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Pilar Lloret-Madrid, Pedro Chorão, Manuel Guerreiro, Pau Montesinos
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Subjects:	acute myeloid leukemia relapsed or refractory AML CAR-T cell therapy
Online Access:	https://www.mdpi.com/1718-7729/32/6/322